You’ve probably been there — staring at another diet plan, another gym ad, another promise of results. And if you’ve ever considered medical help, maybe you stopped short at the thought of needles and weekly injections. That hesitation is more common than you’d think. But something is brewing that could make it all a little easier.
In the U.S., a game-changing step may soon reshape how weight-loss medications are used — and it could make a world of difference for anyone reluctant to start injecting themselves.
A Weight Loss Pill May Be Closer Than You Think
Danish pharma giant Novo Nordisk has submitted a request to U.S. authorities to bring an oral version of Wegovy to the market.
This is the same drug currently taken via injection and known for its impressive results in treating obesity and severe overweight.
While the injectable form has gained widespread use, the idea of a daily pill could be a tipping point — especially for people who’ve been hesitant due to the format.
If approved, this would be the first GLP-1-based weight-loss pill on the U.S. market.
GLP-1 drugs, like Wegovy and Ozempic, work by influencing appetite and metabolism. They’ve transformed the landscape of obesity care in just a few years — and now, that revolution may be expanding beyond the syringe.
Study Results
Novo’s application is backed by a 64-week phase 3 trial involving 307 adults with obesity or overweight. Participants received a daily 25mg oral dose or a placebo. The outcomes appear promising — enough to push the request forward for regulatory review.
What Comes Next?
A decision on the oral version of Wegovy is expected in Q4 of 2025. If approved, it could mark a major milestone for obesity treatment — opening the door to a simpler, more accessible solution for millions.
For those who’ve tried everything from restrictive diets to willpower-fueled gym sessions with little success, a pill might feel like a much more manageable path. And for the industry, it signals a new chapter in a booming field.
This article is based on information from B.T.
This article is made and published by Mie Hermansen, who may have used AI in the preparation.